Abstract: The invention belongs to the technical field of medicine, and particularly relates to nucleoside drugs for the treatment or prevention of coronavirus infection and uses thereof. The present invention also relates to a method for preparing prodrugs of a nucleoside drug. The nucleoside drugs of formula (I) or (II) disclosed herein are more suitable for oral administration to subjects in need as compared to other nucleoside drugs, such as remdesivir for injection.

Abstract: A profile download method includes a primary device obtaining an embedded integrated circuit card identifier (EID) of a secondary device, where the EID is used by the primary device to obtain, from a mobile operator server, profile download information that matches the EID. The primary device receives the profile download information from the mobile operator server and sends the profile download information to the secondary device, where the profile download information is used by the secondary device to download a profile from a profile management server, and where the profile is installed in an embedded UICC (eUICC) of the secondary device after the download is complete.

Abstract: A crystal form (such as formula I) of a 2-methyl-2-propanol and amino-substituted aryl compound and a preparation method therefor. Also provided is an application of the crystal form in the preparation of a medicine for treating related diseases.

Abstract: Indium zinc-based alloy anodes include an InxMyZnz alloy, where x ranges from 0.03 to 0.20, z ranges from 0.80 to 0.97, and x+y+z=1 when the anode has not previously been cycled. M is Al, Ag, Bi, Sn, Cd, or any combination thereof. In a partially or fully discharged state after one or more cycles, the anode includes a porous surface portion enriched in indium and a bulk portion comprising the InxMyZnz alloy. In a subsequent partially or fully charged state, the pores may be at least partially filled with zinc.

Abstract: A crystal form (such as formula I) of a 2-methyl-2-propanol and amino-substituted aryl compound and a preparation method therefor. Also provided is an application of the crystal form in the preparation of a medicine for treating related diseases.

Abstract: An aminopyridine compound that may be used as an aldehyde trapping agent, and specifically disclosed is a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.

Abstract: An interaction method, an interaction apparatus, and an electronic device are provided. The method includes: determining, in response to detecting a predefined size transformation operation, target transformation information of a target video based on whether a current size of the target video is a preset anchor point size, where the target video is a video played in a video play area; and transforming the target video based on the target transformation information, and playing the transformed target video.

Abstract: Electrolytes for lithium ion batteries with carbon-based, silicon-based, or carbon- and silicon-based anodes include a lithium salt; a nonaqueous solvent comprising at least one of the following components: (i) an ester, (ii) a sulfur-containing solvent, (iii) a phosphorus-containing solvent, (iv) an ether, (v) a nitrile, or any combination thereof, wherein the lithium salt is soluble in the solvent; a diluent comprising a fluoroalkyl ether, a fluorinated orthoformate, a fluorinated carbonate, a fluorinated borate, or a combination thereof, wherein the lithium salt has a solubility in the diluent at least 10 times less than a solubility of the lithium salt in the solvent; and an additive having a different composition than the lithium salt, a different composition than the solvent, and a different composition than the diluent.

Abstract: A profile download method includes a primary device obtaining an embedded integrated circuit card identifier (EID) of a secondary device, where the EID is used by the primary device to obtain, from a mobile operator server, profile download information that matches the EID. The primary device receives the profile download information from the mobile operator server and sends the profile download information to the secondary device, where the profile download information is used by the secondary device to download a profile from a profile management server, and where the profile is installed in an embedded UICC (eUICC) of the secondary device after the download is complete.

Abstract: A method for detecting a storage life of a pre-crosslinked material is provided. Tableting is performed on an unaged pre-crosslinked material to obtain crosslinked polyethylene. A crosslinking degree and a mechanical property of the crosslinked polyethylene are measured to obtain reference data. The pre-crosslinked material is heated to obtain a fast-aged pre-crosslinked material. The crosslinking degree and mechanical property of crosslinked polyethylene obtained from the fast-aged pre-crosslinked material are measured to obtain measurement results, which are compared with the reference data. If comparison results all fall within corresponding ranges, the time period of heating is increased by a step to repeat the above steps until the comparison results do not all fall within the corresponding ranges. A result obtained by subtracting the step from the time period of heating is converted into a time period of storage at the room temperature.

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

Abstract: The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof.

Abstract: Provided is a T-cell receptor (TCR) having the characteristic of binding a SLLMWITQC-HLA A0201 complex. The binding affinity to the SLLMWITQC-HLA A0201 complex is at least 2 times that of a wild-type TCR to the SLLMWITQC-HLA A0201 complex. The TCR may be used alone or in combination with a therapeutic agent, so as to target a tumor cell presenting the SLLMWITQC-HLA A0201 complex.

Abstract: Provided in the present invention is a T-cell receptor (TCR) having the characteristic of binding a FMNKFIYEI-HLA A0201 complex. The binding affinity of the TCR to the FMNKFIYEI-HLA A0201 complex is at least 5 times that of a wild-type TCR to the FMNKFIYEI-HLA A0201 complex. Further provided in the present invention is a fusion molecule of the TCR with a therapeutic agent. The TCR may be used alone or in combination with the therapeutic agent, so as to target a tumor cell presenting the FMNKFIYEI-HLA A0201 complex.

Abstract: A wearable device, where the wearable device includes at least two working modes. The at least two working modes include a first working mode and a second working mode. The wearable device receives a user operation, the wearable device starts the first working mode in response to a first operation of a user to collect first activity data, where the first activity data is daily activity data of the user, and the wearable device starts the second working mode in response to a second operation of the user to collect second activity data, where the second activity data is professional exercise data of the user.